Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo
AbCellera Gains Green Light for Clinical Trial; Stock Sees Uptick

Stock News

AbCellera Gains Green Light for Clinical Trial; Stock Sees Uptick

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Updated 6/18/2025, 11:32 am ET 6/18/2025, 11:32 am ET | 4 min 4 min read
AbCellera Gains Green Light for Clinical Trial; Stock Sees Uptick Thumbnail

In this article Last trade Feb, 05 7:44 PM

  • ABCL-14.98%
    ABCL - NYSEAbCellera Biologics Inc.
    $2.74-0.49 (-14.98%)
    Volume:  11.09M
    Float:  209.51M
    $2.75Day Low/High$3.21

AbCellera Biologics Inc.’s stocks have been trading up by 11.54 percent following promising results in antibody engineering.

  • The positive news from Health Canada authorization injected renewed hope, and plans for a Phase 1 trial in Q3 highlight strategic growth in targeted therapy sectors.

  • The investigational therapy, while initially for dermatitis, could pave the way for tackling broader inflammatory and autoimmune conditions.

  • The stock of AbCellera rose due to optimism around the announcement, reflecting investor confidence in the company’s expanding pipeline.

Candlestick Chart

Live Update At 11:31:54 EST: On Wednesday, June 18, 2025 AbCellera Biologics Inc. stock [NASDAQ: ABCL] is trending up by 11.54%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

AbCellera’s recent earnings reveal a mixed bag of financial metrics. The company reported a total revenue for the first quarter of 2025 of roughly $4.23 million, reflecting significant challenges as the operating income hit a loss of $62.66 million. With the current price-to-sales ratio at 80.56, the valuation remains high.

The stock value saw a consistent upward trend from early June, progressing from a baseline around $2.02 to a close of $3.48 around midmonth. During intraday trading, the stock fluctuated but showed resilience, reflecting investor optimism driven by ongoing developments.

While the stock remains volatile with a beta that hints at moderate risk, the upward price movement suggests bullish sentiment around the company’s potential in the clinical landscape.

Market Reactions

The stock increase aligns closely with the recent announcement from AbCellera. Financial markets value advancements in biotechnology highly, especially when linked to major health concerns like dermatitis that impact a wide demographic. For AbCellera, the authorization won’t just expand its pipeline; it could bolster investor trust and potentially reel in partnerships or funding for the projected clinical maturities.

Investors often look at these pivotal moments—like government approval for significant clinical trials—as times to act, hoping to capitalize on future growth dictated by such innovations. The positive market reception offers initial reassurance for stakeholders banking on biotech breakthroughs.

More Breaking News

Conclusion

In summary, the recent developments with Health Canada’s approval for AbCellera’s upcoming clinical trial mark a significant strategic milestone. It emphasizes not only the company’s focus on addressing unmet healthcare needs but also underlines its role in pioneering novel treatments.

Despite facing hurdles with financial losses, the market’s reaction underscores accrued anticipation and optimism. As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.” As the trial progresses, stakeholders will be watching closely to gauge the efficacy and potential market reach of the investigational treatment. Given the current trajectory, the company’s active engagement in research and therapy should capture further trader interest, and any positive trial outcomes may significantly boost ABCL’s market value.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

In this article (YTD Performance)

  • ABCL-7.6%
    ABCL - NYSEAbCellera Biologics Inc.
    $2.74-0.49 (-14.98%)
    Volume:  11.09M
    Float:  209.51M
    $2.75Day Low/High$3.21

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Learn The Formula That Has Created Over 50 Millionaires
TRADE LIKE TIM
notification icon
Subscribe to receive notifications